Sol-Gel Technologies (FRA:4SG) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4SG Sol-Gel Technologies Ltd FRA:4SG
59 GF Score
Price €72.50
GF Value €50.25
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sol-Gel Technologies FFO per Share?

FFO per Share only applies to REITs.

FRA:4SG
59GF Score
Sol-Gel Technologies Ltd FRA:4SG
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sol-Gel Technologies (FRA:4SG) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of €72.50 is trading 44.3% above its estimated GF Value™ of €50.25. GuruFocus considers Sol-Gel Technologies to be Significantly Overvalued.

Key valuation signals for FRA:4SG:

  • FFO per Share:
  • GF Value™: €50.25 vs. price of €72.50 (44.3% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the FRA:4SG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges SLGL:USA
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
59GF Score

Get the complete analysis for FRA:4SG

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.50
Price
€50.25
GF Value